ClinicalTrials.gg
CompletedNCT05267743Updated Jul 29, 2022

Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease

A Phase 4 interventional study of Tegoprazan 50mg QD and Lansoprazole 30mg QD in Erosive Reflux Disease, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-29.

Sponsored by HK inno.N Corporation · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Feb 2021, registered Jul 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Study summary

This study is designed to evaluate the efficacy and safety of Tegoprazan 50mg, compared to Lansoprazole 30mg in patients with healed erosive reflux disease confirmed by endoscopy following oral administration once daily(QD) of 2 weeks or 4 weeks.

Read the detailed description

This is a double blind, radomized, active-controlled, phase 4 study. Subjects will be randomly assigned to one of the two treatment groups (Tegoprazan 50mg, Lansoprazole 30mg)

02

Conditions studied

  • Erosive Reflux Disease
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Erosive eshophagitis(LA calssfication Grades A to D) with in 30 days prior to Randomization
  2. Those who have experienced heartburn symptoms within 7 days prior to Visit 1(screening date)

Exclusion criteria

Exclusion Criteria:

  1. Unalbe to undergo upper GI endoscopy
  2. H. pylori positive
  3. Those who cannot write a clinical trial subject diary
  4. Presence of esophageal stricture, ulcerated stricture, gastroesophageal varix, long segment Barrett's esophagus with >3cm length(LSBE), eosinophilic oesophagitis, active digestive ulcer or gastric bleeding on an upper GI endoscopy
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    Tegoprazan 50mg QD

    Tegoprazan 50mg tablet, once daily, oral administration

    Drug: Tegoprazan 50mg QD

  • Active comparator
    Lansoprazole 30mg QD

    Lansoprazole 30mg capsule, once dauly, oral administration

    Drug: Lansoprazole 30mg QD

Interventions

  • Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.

  • Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.

06

What researchers measure

Primary outcomes

  1. 4 weeks cumulative ERD healing rate(%)

    Healing is defined as "not present" erosions or fissures according to the LA classification.

    Time frame: 4 weeks

Secondary outcomes

  1. 2 weeks ERD healing rate(%)

    Healing is defined as "not present" erosions or fissures according to the LA classification.

    Time frame: 2 weeks

  2. Healing rate(%) at 2 weeks and 4 weeks according to CYP2C19 genotype type

    Extensive Metaboliser (EM), Intermediate Metaboliser (IM), Poor Metaboliser (PM)

    Time frame: 2 weeks or 4 weeks

  3. Percentage of days without heartburn through the clinical trial subject dairy (%)

    On days with no symptoms of heartburn, '0. It is defined as a case assessed as having no symptoms.

    Time frame: 2 weeks or 4 weeks

  4. RDQ (Reflux Disease Questionnaire) evaluation(mean change in severity)

    Average scale change in RDQ severity and frequency at 2 weeks and 4 weeks after administration compared to before administration of investigational drugs for each category (heartburn, indigestion, acid reflux)

    Time frame: 2 weeks or 4 weeks

  5. Incidence of Adverse Events [Safety]

    Physical examination(weight-kg)(height-cm), vital signs(SBP, DBP, heart rate, body temperature), adverse reactions, blood chemistry test

    Time frame: 2 weeks or 4 weeks

07

Study locations

1 site
  • Wonkwang University Hospital
    Iksan, Muwang-ro 895 54538, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in May 2022, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2021
First posted
Mar 4, 2022
StartActual
Feb 16, 2021
Primary completionActual
May 25, 2022
CompletionActual
May 25, 2022
Last update
Jul 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05267743
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Feb 16, 2021
Primary completion
May 25, 2022
Completion
May 25, 2022
Last update
Jul 29, 2022

Study contacts

Suk Chae Choi
principal investigator · Wonkwang University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion